Mini Review
Volume 14:03, 2024

Journal of Sports Medicine & Doping Studies

ISSN: 2161-0673 Open Access

Whole-body Cryostimulation for Multiple Sclerosis Treatment

Julia Pawel*

Department of Surgical Sciences, University of Torino, Torino, Italy

Abstract

Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system that affects millions of individuals worldwide. The disease is characterized by a variety of neurological symptoms, including muscle weakness, fatigue, spasticity, pain, and cognitive impairment. Despite significant advancements in understanding MS, its exact etiology remains elusive, and current treatment modalities primarily focus on managing symptoms and slowing disease progression.

Keywords: Sclerosis • Chronic • Spasticity

Introduction

In recent years, whole-body cryostimulation, a non-invasive therapeutic intervention involving exposure to extremely cold temperatures, has garnered attention as a potential complementary treatment for MS. This mini review aims to explore the current evidence surrounding the use of WBC in MS, including its mechanisms of action, efficacy, and safety profile. One of the primary mechanisms through which WBC is believed to exert its beneficial effects is by modulating inflammatory processes. MS is characterized by chronic inflammation and immune system dysregulation. Exposure to cold temperatures during WBC can lead to a reduction in pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-1 beta, while simultaneously increasing anti-inflammatory cytokines like interleukin-10.

Literature Review

This shift in the cytokine profile helps in mitigating the inflammatory response, thereby potentially reducing the progression of MS and alleviating symptoms. WBC may also offer neuroprotective benefits by reducing oxidative stress, a critical factor in the pathogenesis of MS .Cold exposure can enhance the activity of antioxidant enzymes such as superoxide dismutase and catalase, which help in scavenging reactive oxygen species and reducing neuronal damage Additionally, WBC has been shown to increase the levels of brain-derived neurotrophic factor ,a protein that supports the survival and growth of neurons, which could be beneficial in promoting neuroplasticity and repair in MS patients. The autonomic nervous system plays a significant role in the regulation of physiological responses [1].

WBC can influence the ANS by stimulating the parasympathetic nervous system and reducing sympathetic overactivity, which is often observed in MS patients. This modulation can lead to improvements in cardiovascular function, sleep quality, and overall well-being .MS patients often experience significant pain and spasticity. WBC has been reported to reduce these symptoms by decreasing muscle tone and enhancing endorphin release. The analgesic effects of WBC are believed to result from the cold-induced release of endorphins and the reduction in nerve conduction velocity, which can diminish pain perception [2].

***Address for Correspondence:** Julia Pawel, Department of Surgical Sciences, University of Torino, Torino, Italy, E-mail: Paweljuli@gmail.com*

Received: 01 May, 2024, Manuscript No. Jsmds-24-138626; **Editor Assigned:** 03 May, 2024, PreQC No. P-138626; **Reviewed:** 17 May, 2024, QC No. Q-138626; **Revised:** 22 May, 2024, Manuscript No. R-138626; **Published:** 29 May, 2024, DOI: 10.37421/2161-0673.2024.14.363

Discussion

Several clinical studies and trials have investigated the efficacy of WBC in MS, with promising results. A study by Miller et al. demonstrated that WBC significantly improved fatigue and quality of life in MS patients after a series of 10 sessions over two weeks. Another randomized controlled trial by Hausswirth, et al. reported that WBC improved spasticity and pain levels in MS patients, with effects lasting up to four weeks post-treatment. Fatigue is one of the most debilitating symptoms of MS, significantly impacting daily activities and quality of life. WBC has been shown to reduce fatigue levels, potentially by modulating inflammatory markers and improving sleep quality [3].

Additionally, the analgesic effects of WBC can contribute to reduced pain and spasticity, further enhancing the overall functionality and comfort of MS patients. Improvements in physical function, including enhanced mobility and muscle strength, have been observed following WBC sessions. These benefits are likely due to the combined effects of reduced spasticity, pain relief, and improved neuromuscular function. Moreover, some studies suggest that WBC may have positive effects on cognitive function, possibly through the modulation of neuroinflammatory processes and enhanced neuroplasticity [4].

WBC is generally considered safe when conducted under professional supervision. However, potential adverse effects can include cold-induced urticaria, frostbite, and transient increases in blood pressure. These risks can be minimized by adhering to established safety protocols, including appropriate screening of patients for contraindications and ensuring proper exposure times and temperatures. Contraindications for WBC include conditions such as Raynaud's disease, cold agglutinin disease, severe cardiovascular disorders, and uncontrolled hypertension. It is crucial for healthcare providers to thoroughly assess patients' medical histories and conduct appropriate screenings before initiating WBC treatment to mitigate potential risks [5].

Standardized protocols for WBC in MS are still under development, with variations in exposure times, temperatures, and session frequencies observed across studies. Treatment regimens typically consist of multiple sessions over a period of weeks to achieve optimal benefits. WBC should be considered as an adjunctive therapy rather than a standalone treatment for MS. Integrating WBC with conventional pharmacological treatments, physical therapy, and lifestyle modifications may offer a synergistic approach to managing MS symptoms and improving patients' quality of life.

It is essential for healthcare providers to work collaboratively with patients to develop individualized treatment plans that incorporate WBC in a manner that complements other therapeutic interventions. While preliminary studies on WBC in MS are promising, there is a need for larger, well-designed clinical trials to confirm its efficacy and safety. Research should focus on optimizing treatment protocols, understanding the long-term effects of WBC, and

elucidating the precise mechanisms through which it exerts its benefits. The future of WBC in MS may lie in personalized medicine approaches, where treatments are tailored to individual patients based on their unique clinical profiles, genetic backgrounds, and disease characteristics.

Advances in biomarker research and precision medicine could help identify which patients are most likely to benefit from WBC, leading to more targeted and effective therapeutic interventions. Technological advancements in cryotherapy equipment and monitoring tools could enhance the safety, efficacy, and accessibility of WBC. Improved devices with precise temperature control, real-time monitoring of physiological responses, and personalized treatment settings could revolutionize the application of WBC in MS and other medical conditions [6].

Conclusion

Whole-body cryostimulation represents a promising complementary therapy for managing symptoms and potentially modifying disease progression in multiple sclerosis. Its anti-inflammatory, neuroprotective, and analgesic effects offer significant benefits for MS patients, particularly in reducing fatigue, pain, and spasticity. While the current evidence is encouraging, further research is necessary to establish standardized treatment protocols, confirm long-term safety and efficacy, and explore personalized approaches to WBC in MS.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ghasemi, Nazem, Shahnaz Razavi and Elham Nikzad. "Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy." *Cell J* 19 (2017):1.
2. Ramagopalan, Sreeram V. and A. Dessa Sadovnick. "Epidemiology of multiple sclerosis." *Neurol Clin* 29 (2011): 207-217.
3. Dimitrov, Lilia G. and Benjamin Turner. "What's new in multiple sclerosis?." *Br J Gen Pract* 64 (2014): 612-613.
4. Barkhane, Zineb, Jalal Elmadi, Lakshmi Satish Kumar and Lakshmi Sree Pugalenthi, et al. "Multiple sclerosis and autoimmunity: A veiled relationship." *Cureus* 14 (2022).
5. Landry, Remi L. and Monica E. Embers. "The Probable Infectious Origin of Multiple Sclerosis." *Neuro Sci* 4 (2023): 211-234.
6. Briones-Buixassa, Laia, Raimon Milà, Josep Mª Aragonès and Enric Bufill, et al. "Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress." *Health Psychol Open* 2 (2015): 2055102915612271.

How to cite this article: Pawel, Julia. "Whole-body Cryostimulation for Multiple Sclerosis Treatment." *J Sports Med Doping Stud* 14 (2024): 363.